
    
      This is a phase II, open-label, non-randomized study that will be conducted in patients
      affected by advanced or metastatic colorectal cancer (CRC), previously treated with
      fluoropyrimidine, oxaliplatin and irinotecan based regimens, that will be conducted using
      Simon's two-stage design method.
    
  